English
Insider transactions
EDGARAclaris Therapeutics, Inc.
Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.
A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.
Window: transactions dated on or after 2025-11-20.
- Open-market purchases (code P)
- 0 transactions, — shares
- Open-market sales (code S)
- 1 transactions, 300,000 shares
- Sum of shares × price per share: 1,359,000
Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.
Showing 1–50 of 87
| Date | Reporting owner | Code | Acquired or disposed | Shares | Price per share, as filed | Value (derived) | Shares owned after | Direct or indirect | Rule 10b5-1 box | Notes | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-08-01 Filed 2026-08-04 | Kolbeck Roland Wilhelm Officer: Chief Scientific Officer | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Acquired (A) | 36,375 | — | — | 36,375 | Direct (D) | No | F1
| Open filing 0002076327-26-000006 Read from the filing’s XML Dispute this row |
| 2026-08-01 Filed 2026-08-04 | Kolbeck Roland Wilhelm Officer: Chief Scientific Officer | FPayment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | Disposed (D) | 12,385 | 5.20 | 64,402Derived: shares × price per share. Exact value 64402.00. | 23,990 | Direct (D) | No | F2
| Open filing 0002076327-26-000006 Read from the filing’s XML Dispute this row |
| 2026-08-01 Filed 2026-08-04 | Kolbeck Roland Wilhelm Officer: Chief Scientific Officer | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Disposed (D) | 36,375 | 0 | — | 109,125 | Direct (D) | No | F1, F3
| Open filing 0002076327-26-000006 Read from the filing’s XML Dispute this row |
| 2026-06-05 Filed 2026-06-08 | Humphries William D. Director | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Acquired (A) | 11,580 | — | — | 45,105 | Direct (D) | No | F1
| Open filing 0001674278-26-000002 Read from the filing’s XML Dispute this row |
| 2026-06-05 Filed 2026-06-08 | Humphries William D. Director | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Disposed (D) | 11,580 | 0 | — | 0 | Direct (D) | No | F1, F5
| Open filing 0001674278-26-000002 Read from the filing’s XML Dispute this row |
| 2026-06-05 Filed 2026-06-08 | Mehra Anand Director | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Acquired (A) | 11,580 | — | — | 726,403 | Direct (D) | No | F1
| Open filing 0001590102-26-000002 Read from the filing’s XML Dispute this row |
| 2026-06-05 Filed 2026-06-08 | Mehra Anand Director | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Disposed (D) | 11,580 | 0 | — | 0 | Direct (D) | No | F1, F5
| Open filing 0001590102-26-000002 Read from the filing’s XML Dispute this row |
| 2026-06-05 Filed 2026-06-08 | Molineaux Christopher P. Director | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Acquired (A) | 11,580 | — | — | 69,536 | Direct (D) | No | F1
| Open filing 0001654773-26-000003 Read from the filing’s XML Dispute this row |
| 2026-06-05 Filed 2026-06-08 | Molineaux Christopher P. Director | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Disposed (D) | 11,580 | 0 | — | 0 | Direct (D) | No | F1, F5
| Open filing 0001654773-26-000003 Read from the filing’s XML Dispute this row |
| 2026-06-05 Filed 2026-06-08 | GOWEN MAXINE Director | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Acquired (A) | 11,580 | — | — | 33,334 | Direct (D) | No | F1
| Open filing 0001280044-26-000004 Read from the filing’s XML Dispute this row |
| 2026-06-05 Filed 2026-06-08 | GOWEN MAXINE Director | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Disposed (D) | 11,580 | 0 | — | 0 | Direct (D) | No | F1, F5
| Open filing 0001280044-26-000004 Read from the filing’s XML Dispute this row |
| 2026-06-05 Filed 2026-06-08 | SCHIFF ANDREW N Director | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Acquired (A) | 11,580 | — | — | 25,540 | Direct (D) | No | F1
| Open filing 0001172252-26-000002 Read from the filing’s XML Dispute this row |
| 2026-06-05 Filed 2026-06-08 | SCHIFF ANDREW N Director | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Disposed (D) | 11,580 | 0 | — | 0 | Direct (D) | No | F1, F6
| Open filing 0001172252-26-000002 Read from the filing’s XML Dispute this row |
| 2026-06-05 Filed 2026-06-08 | MILANO VINCENT Director | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Acquired (A) | 11,580 | — | — | 28,896 | Direct (D) | No | F1
| Open filing 0001187159-26-000002 Read from the filing’s XML Dispute this row |
| 2026-06-05 Filed 2026-06-08 | MILANO VINCENT Director | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Disposed (D) | 11,580 | 0 | — | 0 | Direct (D) | No | F1, F5
| Open filing 0001187159-26-000002 Read from the filing’s XML Dispute this row |
| 2026-06-04 Filed 2026-06-08 | Humphries William D. Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 42,350 | 0 | — | 42,350 | Direct (D) | No | F2, F3
| Open filing 0001674278-26-000002 Read from the filing’s XML Dispute this row |
| 2026-06-04 Filed 2026-06-08 | Humphries William D. Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 10,987 | 0 | — | 10,987 | Direct (D) | No | F1, F4, F3
| Open filing 0001674278-26-000002 Read from the filing’s XML Dispute this row |
| 2026-06-04 Filed 2026-06-08 | Mehra Anand Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 42,350 | 0 | — | 42,350 | Direct (D) | No | F2, F3
| Open filing 0001590102-26-000002 Read from the filing’s XML Dispute this row |
| 2026-06-04 Filed 2026-06-08 | Mehra Anand Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 10,987 | 0 | — | 10,987 | Direct (D) | No | F1, F4, F3
| Open filing 0001590102-26-000002 Read from the filing’s XML Dispute this row |
| 2026-06-04 Filed 2026-06-08 | Molineaux Christopher P. Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 42,350 | 0 | — | 42,350 | Direct (D) | No | F2, F3
| Open filing 0001654773-26-000003 Read from the filing’s XML Dispute this row |
| 2026-06-04 Filed 2026-06-08 | Molineaux Christopher P. Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 10,987 | 0 | — | 10,987 | Direct (D) | No | F1, F4, F3
| Open filing 0001654773-26-000003 Read from the filing’s XML Dispute this row |
| 2026-06-04 Filed 2026-06-08 | GOWEN MAXINE Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 42,350 | 0 | — | 42,350 | Direct (D) | No | F2, F3
| Open filing 0001280044-26-000004 Read from the filing’s XML Dispute this row |
| 2026-06-04 Filed 2026-06-08 | GOWEN MAXINE Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 10,987 | 0 | — | 10,987 | Direct (D) | No | F1, F4, F3
| Open filing 0001280044-26-000004 Read from the filing’s XML Dispute this row |
| 2026-06-04 Filed 2026-06-08 | SCHIFF ANDREW N Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 42,350 | 0 | — | 42,350 | Direct (D) | No | F3, F4
| Open filing 0001172252-26-000002 Read from the filing’s XML Dispute this row |
| 2026-06-04 Filed 2026-06-08 | SCHIFF ANDREW N Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 10,987 | 0 | — | 10,987 | Direct (D) | No | F1, F5, F4
| Open filing 0001172252-26-000002 Read from the filing’s XML Dispute this row |
| 2026-06-04 Filed 2026-06-08 | MILANO VINCENT Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 42,350 | 0 | — | 42,350 | Direct (D) | No | F2, F3
| Open filing 0001187159-26-000002 Read from the filing’s XML Dispute this row |
| 2026-06-04 Filed 2026-06-08 | MILANO VINCENT Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 10,987 | 0 | — | 10,987 | Direct (D) | No | F1, F4, F3
| Open filing 0001187159-26-000002 Read from the filing’s XML Dispute this row |
| 2026-05-01 Filed 2026-05-05 | Hall Jesse Wayne Officer: Chief Medical Officer | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Acquired (A) | 36,375 | — | — | 36,375 | Direct (D) | No | F1
| Open filing 0002065269-26-000004 Read from the filing’s XML Dispute this row |
| 2026-05-01 Filed 2026-05-05 | Hall Jesse Wayne Officer: Chief Medical Officer | FPayment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | Disposed (D) | 9,330 | 4.41 | 41,145.3Derived: shares × price per share. Exact value 41145.30. | 27,045 | Direct (D) | No | F2
| Open filing 0002065269-26-000004 Read from the filing’s XML Dispute this row |
| 2026-05-01 Filed 2026-05-05 | Hall Jesse Wayne Officer: Chief Medical Officer | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Disposed (D) | 36,375 | 0 | — | 109,125 | Direct (D) | No | F1, F3
| Open filing 0002065269-26-000004 Read from the filing’s XML Dispute this row |
| 2026-04-23 Filed 2026-04-27 | Leonard Braden Michael 10% owner | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 300,000 | 4.53 | 1,359,000Derived: shares × price per share. Exact value 1359000.00. | 13,950,000 | Indirect (I) Holdings of BML Investment Partners, L.P. | No | F1
| Open filing 0001373604-26-000034 Read from the filing’s XML Dispute this row |
| 2026-03-01 Filed 2026-03-03 | Balthaser Kevin Officer: Chief Financial Officer | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Acquired (A) | 2,375 | — | — | 188,130 | Direct (D) | No | F1
| Open filing 0001957554-26-000011 Read from the filing’s XML Dispute this row |
| 2026-03-01 Filed 2026-03-03 | Balthaser Kevin Officer: Chief Financial Officer | FPayment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | Disposed (D) | 677 | 2.87 | 1,942.99Derived: shares × price per share. Exact value 1942.99. | 187,453 | Direct (D) | No | F2
| Open filing 0001957554-26-000011 Read from the filing’s XML Dispute this row |
| 2026-03-01 Filed 2026-03-03 | Balthaser Kevin Officer: Chief Financial Officer | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Disposed (D) | 2,375 | 0 | — | 0 | Direct (D) | No | F1, F3
| Open filing 0001957554-26-000011 Read from the filing’s XML Dispute this row |
| 2026-02-03 Filed 2026-02-05 | Balthaser Kevin Officer: Chief Financial Officer | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Acquired (A) | 22,025 | — | — | 192,204 | Direct (D) | No | F1
| Open filing 0001957554-26-000007 Read from the filing’s XML Dispute this row |
| 2026-02-03 Filed 2026-02-05 | Balthaser Kevin Officer: Chief Financial Officer | FPayment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | Disposed (D) | 6,449 | 3.47 | 22,378.03Derived: shares × price per share. Exact value 22378.03. | 185,755 | Direct (D) | No | F2
| Open filing 0001957554-26-000007 Read from the filing’s XML Dispute this row |
| 2026-02-03 Filed 2026-02-05 | Balthaser Kevin Officer: Chief Financial Officer | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Disposed (D) | 22,025 | 0 | — | 66,075 | Direct (D) | No | F1, F3
| Open filing 0001957554-26-000007 Read from the filing’s XML Dispute this row |
| 2026-02-03 Filed 2026-02-05 | Walker Neal Director · Officer: CEO | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Acquired (A) | 63,475 | — | — | 1,562,497 | Direct (D) | No | F1
| Open filing 0001604457-26-000005 Read from the filing’s XML Dispute this row |
| 2026-02-03 Filed 2026-02-05 | Walker Neal Director · Officer: CEO | FPayment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | Disposed (D) | 18,611 | 3.47 | 64,580.17Derived: shares × price per share. Exact value 64580.17. | 1,543,886 | Direct (D) | No | F2
| Open filing 0001604457-26-000005 Read from the filing’s XML Dispute this row |
| 2026-02-03 Filed 2026-02-05 | Walker Neal Director · Officer: CEO | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Disposed (D) | 63,475 | 0 | — | 190,425 | Direct (D) | No | F1, F3
| Open filing 0001604457-26-000005 Read from the filing’s XML Dispute this row |
| 2026-02-03 Filed 2026-02-05 | Loerop James Officer: Chief Business Officer | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Acquired (A) | 20,875 | — | — | 198,197 | Direct (D) | No | F1
| Open filing 0001781549-26-000011 Read from the filing’s XML Dispute this row |
| 2026-02-03 Filed 2026-02-05 | Loerop James Officer: Chief Business Officer | FPayment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | Disposed (D) | 5,937 | 3.47 | 20,601.39Derived: shares × price per share. Exact value 20601.39. | 192,260 | Direct (D) | No | F2
| Open filing 0001781549-26-000011 Read from the filing’s XML Dispute this row |
| 2026-02-03 Filed 2026-02-05 | Loerop James Officer: Chief Business Officer | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Disposed (D) | 20,875 | 0 | — | 62,625 | Direct (D) | No | F1, F3
| Open filing 0001781549-26-000011 Read from the filing’s XML Dispute this row |
| 2026-02-03 Filed 2026-02-05 | Davis Hugh M. Director · Officer: President and COO | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Acquired (A) | 18,675 | — | — | 45,425 | Direct (D) | No | F1
| Open filing 0002045027-26-000002 Read from the filing’s XML Dispute this row |
| 2026-02-03 Filed 2026-02-05 | Davis Hugh M. Director · Officer: President and COO | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Disposed (D) | 18,675 | 0 | — | 56,025 | Direct (D) | No | F1, F2
| Open filing 0002045027-26-000002 Read from the filing’s XML Dispute this row |
| 2026-02-02 Filed 2026-02-06 | Loerop James Officer: Chief Business Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 97,700 | 0 | — | 97,700 | Direct (D) | No | F1, F2
| Open filing 0001781549-26-000013 Read from the filing’s XML Dispute this row |
| 2026-02-02 Filed 2026-02-06 | Loerop James Officer: Chief Business Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 341,900 | 0 | — | 341,900 | Direct (D) | No | F3
| Open filing 0001781549-26-000013 Read from the filing’s XML Dispute this row |
| 2026-02-02 Filed 2026-02-06 | Balthaser Kevin Officer: Chief Financial Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 99,100 | 0 | — | 99,100 | Direct (D) | No | F1, F2
| Open filing 0001957554-26-000009 Read from the filing’s XML Dispute this row |
| 2026-02-02 Filed 2026-02-06 | Balthaser Kevin Officer: Chief Financial Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 346,800 | 0 | — | 346,800 | Direct (D) | No | F3
| Open filing 0001957554-26-000009 Read from the filing’s XML Dispute this row |
| 2026-02-02 Filed 2026-02-06 | Hall Jesse Wayne Officer: Chief Medical Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 98,100 | 0 | — | 98,100 | Direct (D) | No | F1, F2
| Open filing 0002065269-26-000002 Read from the filing’s XML Dispute this row |
Institutional holders (Form 13F)
Quarter ending 2026-09-30: 8,905 filings read, the latest filed 2026-11-18. Prior quarter ending 2026-06-30: 9,170 filings read.
Showing 1–50 of 179
| Manager | Shares or principal | Value as filed | Change from the prior quarter | Source |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 12,723,026 SH | 66,923,117 dollars | Unchanged Prior quarter: 12,723,026 | Open filing 0001104659-26-128411 Filed 2026-11-16 Dispute this row |
| BML Capital Management, LLC | 10,955,000 SH | 57,623,300 dollars | Lower by 1,020,000 Prior quarter: 11,975,000 | Open filing 0001754960-26-000981 Filed 2026-11-06 Dispute this row |
| BlackRock, Inc. Partly reported under another manager | 10,376,592 SH | 54,580,873 dollars | Higher by 339,584 Prior quarter: 10,037,008 | Open filing 0002012383-26-003985 Filed 2026-11-13 Dispute this row |
| Deep Track Capital, LP | 9,345,000 SH | 49,154,700 dollars | Unchanged Prior quarter: 9,345,000 | Open filing 0001856083-26-000006 Filed 2026-11-16 Dispute this row |
| Frazier Life Sciences Management, L.P. | 8,729,516 SH | 45,917,254 dollars | Higher by 3,804,142 Prior quarter: 4,925,374 | Open filing 0001892134-26-000007 Filed 2026-11-16 Dispute this row |
| FMR LLC Partly reported under another manager | 7,048,161 SH | 37,073,326 dollars | Higher by 6,734,311 Prior quarter: 313,850 | Open filing 0000315066-26-002964 Filed 2026-11-10 Dispute this row |
| Vivo Capital, LLC | 6,694,637 SH | 35,213,791 dollars | Unchanged Prior quarter: 6,694,637 | Open filing 0001213900-26-119459 Filed 2026-11-13 Dispute this row |
| VANGUARD CAPITAL MANAGEMENT LLC | 5,864,619 SH | 30,847,896 dollars | Higher by 46,753 Prior quarter: 5,817,866 | Open filing 0002100119-26-001711 Filed 2026-11-13 Dispute this row |
| MPM BIOIMPACT LLC | 5,178,127 SH | 27,236,948 dollars | Higher by 4,135,660 Prior quarter: 1,042,467 | Open filing 0001193125-26-463462 Filed 2026-11-16 Dispute this row |
| Decheng Capital LLC | 4,041,736 SH | 21,259,531 dollars | Unchanged Prior quarter: 4,041,736 | Open filing 0001104659-26-127247 Filed 2026-11-13 Dispute this row |
| Rock Springs Capital Management LP | 3,791,117 SH | 19,941,275 dollars | Lower by 539,415 Prior quarter: 4,330,532 | Open filing 0001172661-26-005279 Filed 2026-11-16 Dispute this row |
| STATE STREET CORP Partly reported under another manager | 3,696,144 SH | 19,441,717 dollars | Higher by 440,804 Prior quarter: 3,255,340 | Open filing 0000093751-26-000747 Filed 2026-11-12 Dispute this row |
| GEODE CAPITAL MANAGEMENT, LLC Partly reported under another manager | 3,585,794 SH | 18,865,362 dollars | Higher by 395,736 Prior quarter: 3,190,058 | Open filing 0001214717-26-000012 Filed 2026-11-06 Dispute this row |
| Jones Hill Capital LP | 2,504,651 SH | 13,174,464 dollars | Higher by 745,159 Prior quarter: 1,759,492 | Open filing 0002102314-26-000006 Filed 2026-11-13 Dispute this row |
| STEMPOINT CAPITAL LP | 2,050,698 SH | 10,786,671 dollars | Not in the prior quarter’s filings read | Open filing 0001420506-26-002774 Filed 2026-11-16 Dispute this row |
| Siren, L.L.C. Partly reported under another manager | 2,025,000 SH | 10,651,500 dollars | Not in the prior quarter’s filings read | Open filing 0002005245-26-000013 Filed 2026-11-12 Dispute this row |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 1,871,000 SH | 9,841,460 dollars | Lower by 2,200,000 Prior quarter: 4,071,000 | Open filing 0001172661-26-005200 Filed 2026-11-16 Dispute this row |
| Kalehua Capital Management LLC | 1,832,365 SH | 9,638,240 dollars | Lower by 1,832,365 Prior quarter: 3,664,730 | Open filing 0002106181-26-000010 Filed 2026-11-13 Dispute this row |
| CITADEL ADVISORS LLC Partly reported under another manager | 1,775,495 SH | 9,339,104 dollars | Higher by 13,414 Prior quarter: 1,762,081 | Open filing 0001104659-26-128228 Filed 2026-11-16 Dispute this row |
| BRAIDWELL LP | 1,753,978 SH | 9,225,924 dollars | Lower by 388,370 Prior quarter: 2,142,348 | Open filing 0001420506-26-002894 Filed 2026-11-16 Dispute this row |
| Cormorant Asset Management, LP Partly reported under another manager | 1,750,000 SH | 9,205,000 dollars | Not in the prior quarter’s filings read | Open filing 0001583977-26-000011 Filed 2026-11-16 Dispute this row |
| PANAGORA ASSET MANAGEMENT INC | 1,479,505 SH | 7,782,196 dollars | Higher by 123,353 Prior quarter: 1,356,152 | Open filing 0000883677-26-000011 Filed 2026-11-12 Dispute this row |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 1,421,966 SH | 7,479,541 dollars | Lower by 43,769 Prior quarter: 1,465,735 | Open filing 0002100121-26-001150 Filed 2026-11-13 Dispute this row |
| Balyasny Asset Management L.P. | 1,410,299 SH | 7,418,173 dollars | Lower by 613,171 Prior quarter: 2,023,470 | Open filing 0001193125-26-463223 Filed 2026-11-16 Dispute this row |
| ACADIAN ASSET MANAGEMENT LLC Partly reported under another manager | 1,353,997 SH | 7,120 dollars | Lower by 287,475 Prior quarter: 1,641,472 | Open filing 0001140361-26-042753 Filed 2026-11-09 Dispute this row |
| Woodline Partners LP | 1,213,446 SH | 6,382,726 dollars | Lower by 397,608 Prior quarter: 1,611,054 | Open filing 0001172661-26-005063 Filed 2026-11-16 Dispute this row |
| Squadron Capital Management LLC | 1,200,000 SH | 6,312,000 dollars | Not in the prior quarter’s filings read | Open filing 0002050709-26-000036 Filed 2026-11-16 Dispute this row |
| GOLDMAN SACHS GROUP INC Partly reported under another manager | 1,193,916 SH | 6,279,998 dollars | Higher by 584,758 Prior quarter: 609,158 | Open filing 0000886982-26-000647 Filed 2026-11-16 Dispute this row |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1,187,780 SH | 6,247,723 dollars | Higher by 841,722 Prior quarter: 346,058 | Open filing 0000884546-26-000417 Filed 2026-11-16 Dispute this row |
| Palo Alto Investors LP | 1,156,396 SH | 6,082,643 dollars | Lower by 457,034 Prior quarter: 1,613,430 | Open filing 0002073679-26-000180 Filed 2026-11-16 Dispute this row |
| NORTHERN TRUST CORP Partly reported under another manager | 1,003,635 SH | 5,279,120 dollars | Higher by 4,872 Prior quarter: 998,763 | Open filing 0000073124-26-000067 Filed 2026-11-16 Dispute this row |
| VANGUARD FIDUCIARY TRUST CO | 941,759 SH | 4,953,652 dollars | Higher by 34,586 Prior quarter: 907,173 | Open filing 0000933478-26-000017 Filed 2026-11-13 Dispute this row |
| Aldebaran Capital, LLC | 936,185 SH | 4,924,333 dollars | Lower by 546 Prior quarter: 936,731 | Open filing 0001376474-26-000722 Filed 2026-11-13 Dispute this row |
| Connor, Clark Lunn Investment Management Ltd. | 921,271 SH | 4,845,885 dollars | Lower by 288,615 Prior quarter: 1,209,886 | Open filing 0001596800-26-000018 Filed 2026-11-10 Dispute this row |
| FRANKLIN TEMPLETON INC Partly reported under another manager | 871,027 SH | 3,205,379 dollars | Not in the prior quarter’s filings read | Open filing 0000038777-26-000291 Filed 2026-11-12 Dispute this row |
| ExodusPoint Capital Management, LP | 829,157 SH | 4,361,366 dollars | Not in the prior quarter’s filings read | Open filing 0001736225-26-000013 Filed 2026-11-16 Dispute this row |
| Invesco Ltd. Partly reported under another manager | 812,563 SH | 4,274,081 dollars | Higher by 569,535 Prior quarter: 243,028 | Open filing 0000914208-26-000462 Filed 2026-11-12 Dispute this row |
| Three Bridge Wealth Advisors, LLC | 714,823 SH | 3,759,969 dollars | Unchanged Prior quarter: 714,823 | Open filing 0001420506-26-002510 Filed 2026-11-05 Dispute this row |
| MARSHALL WACE, LLP Partly reported under another manager | 630,857 SH | 3,318,310 dollars | Not in the prior quarter’s filings read | Open filing 0001318757-26-000012 Filed 2026-11-13 Dispute this row |
| DIMENSIONAL FUND ADVISORS LP Partly reported under another manager | 513,840 SH | 2,703,077 dollars | Unchanged Prior quarter: 513,840 | Open filing 0000354204-26-001096 Filed 2026-11-04 Dispute this row |
| CITADEL ADVISORS LLC Option: Call Partly reported under another manager | 487,100 SH | 2,562,146 dollars | Lower by 33,900 Prior quarter: 521,000 | Open filing 0001104659-26-128228 Filed 2026-11-16 Dispute this row |
| UBS Group AG Partly reported under another manager | 484,501 SH | 2,548,476 dollars | Higher by 227,500 Prior quarter: 257,001 | Open filing 0001610520-26-000121 Filed 2026-11-10 Dispute this row |
| JPMORGAN CHASE CO Partly reported under another manager | 460,952 SH | 2,433,827 dollars | Lower by 8,012 Prior quarter: 468,964 | Open filing 0000019617-26-000404 Filed 2026-11-12 Dispute this row |
| BARCLAYS PLC Partly reported under another manager | 447,830 SH | 2,355,585 dollars | Higher by 374,820 Prior quarter: 73,010 | Open filing 0000312069-26-000241 Filed 2026-11-06 Dispute this row |
| Aisling Capital Management LP | 434,455 SH | 2,285,233 dollars | Unchanged Prior quarter: 434,455 | Open filing 0001766721-26-000004 Filed 2026-11-12 Dispute this row |
| Bollard Group LLC | 431,631 SH | 2,270 dollars | Unchanged Prior quarter: 431,631 | Open filing 0000929638-26-004282 Filed 2026-11-13 Dispute this row |
| WELLINGTON MANAGEMENT GROUP LLP Partly reported under another manager | 426,874 SH | 2,245,358 dollars | Higher by 159,376 Prior quarter: 267,498 | Open filing 0000902219-26-000323 Filed 2026-11-16 Dispute this row |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP Partly reported under another manager | 411,816 SH | 2,166,152 dollars | Lower by 733 Prior quarter: 412,549 | Open filing 0001446194-26-000009 Filed 2026-11-16 Dispute this row |
| FRED ALGER MANAGEMENT, LLC | 360,412 SH | 1,895,767 dollars | Not in the prior quarter’s filings read | Open filing 0001193125-26-463608 Filed 2026-11-16 Dispute this row |
| Qube Research Technologies Ltd | 326,939 SH | 1,719,699 dollars | Not in the prior quarter’s filings read | Open filing 0001729829-26-000018 Filed 2026-11-13 Dispute this row |
Managers in the prior quarter with no filing read for the latest
They may simply not have filed yet: absent from the latest quarter’s filings read is not the same as a position sold.
- ORBIMED ADVISORS LLC 421,500 SH
- D. E. Shaw Co., Inc. 414,499 SH
- Tetragon Partners GP Ltd 400,000 SH
- Sixth Street Partners Management Company, L.P. 346,058 SH
- SUPERSTRING CAPITAL MANAGEMENT LP 257,675 SH
- Logos Global Management LP 200,000 SH
- Atom Investors LP 148,855 SH
- CenterBook Partners LP 118,228 SH
- Verition Fund Management LLC 98,000 SH
- MANGROVE PARTNERS IM, LLC 50,291 SH
- SG Americas Securities, LLC 34,814 SH
- State of Wyoming 27,439 SH
- INTECH INVESTMENT MANAGEMENT LLC 24,668 SH
- Walleye Capital LLC 19,576 SH
- Empirical Financial Services, LLC d.b.a. Empirical Wealth Management 16,072 SH
- Dynamic Technology Lab Private Ltd 13,521 SH
- TWO SIGMA SECURITIES, LLC 12,671 SH
- Jefferies Financial Group Inc. 11,000 SH
- JANE STREET GROUP, LLC 10,300 SH
- SIMPLEX TRADING, LLC 5,499 SH
- Optiver Holding B.V. 336 SH
- Integrated Wealth Concepts LLC 211 SH
- Truvestments Capital LLC 150 SH
- NATIONAL BANK OF CANADA /FI/ 102 SH
- Form 13F covers long positions in Section 13(f) securities only: no short positions and no securities outside that list.
- A manager that has not yet filed for the latest quarter is absent, not at zero; filings are due up to 45 days after quarter end.
- A change is the difference between two quarter-end snapshots, not a trade.
- A position reported under another manager may also appear in that manager’s filing; rows are not added together.
- Holdings the securities list cannot place with this company, or places ambiguously, are not shown.
Trades by members of Congress
Periodic transaction reports filed by U.S. House members that name this company’s stock. Dates and amounts are as filed.
No House member’s trade in this company is placed in the store. A trade not yet filed or not linked to a company is absent, not zero.
5% holders (Schedule 13D and 13G)
Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.
| Holder | Percent of class | Shares held | Event date | Form | Source |
|---|---|---|---|---|---|
| Biosion, Inc. Common Stock, $0.00001 par value | 4.7 | 7,521,300 | 09/30/2026 Filed 2026-11-16 | SCHEDULE 13G/AAmendment 2 | Open filing 0000929638-26-004367 Dispute this row |
| Bonita Biotech (HK) Ltd Common Stock, $0.00001 par value | 4.7 | 7,521,300 | 09/30/2026 Filed 2026-11-16 | SCHEDULE 13G/AAmendment 2 | Open filing 0000929638-26-004367 Dispute this row |
| Frazier Life Sciences Public Fund, L.P. Common Stock, $0.00001 par value | 5.4 | 7,879,943.00 | 09/14/2026 Filed 2026-09-21 | SCHEDULE 13G | Open filing 0001231919-26-001199 Dispute this row |
| FHMLSP, L.P. Common Stock, $0.00001 par value | 5.4 | 7,879,943.00 | 09/14/2026 Filed 2026-09-21 | SCHEDULE 13G | Open filing 0001231919-26-001199 Dispute this row |
| FHMLSP, L.L.C. Common Stock, $0.00001 par value | 5.4 | 7,879,943.00 | 09/14/2026 Filed 2026-09-21 | SCHEDULE 13G | Open filing 0001231919-26-001199 Dispute this row |
| Frazier Life Sciences XI, L.P. Common Stock, $0.00001 par value | 0.1 | 86,910.00 | 09/14/2026 Filed 2026-09-21 | SCHEDULE 13G | Open filing 0001231919-26-001199 Dispute this row |
| FHMLS XI, L.P. Common Stock, $0.00001 par value | 0.1 | 86,910.00 | 09/14/2026 Filed 2026-09-21 | SCHEDULE 13G | Open filing 0001231919-26-001199 Dispute this row |
| FHMLS XI, L.L.C. Common Stock, $0.00001 par value | 0.1 | 86,910.00 | 09/14/2026 Filed 2026-09-21 | SCHEDULE 13G | Open filing 0001231919-26-001199 Dispute this row |
| Frazier Life Sciences XII, L.P. Common Stock, $0.00001 par value | 0.5 | 762,663.00 | 09/14/2026 Filed 2026-09-21 | SCHEDULE 13G | Open filing 0001231919-26-001199 Dispute this row |
| FHMLS XII, L.P. Common Stock, $0.00001 par value | 0.5 | 762,663.00 | 09/14/2026 Filed 2026-09-21 | SCHEDULE 13G | Open filing 0001231919-26-001199 Dispute this row |
| FHMLS XII, L.L.C. Common Stock, $0.00001 par value | 0.5 | 762,663.00 | 09/14/2026 Filed 2026-09-21 | SCHEDULE 13G | Open filing 0001231919-26-001199 Dispute this row |
| RA Capital Management, L.P. Common Stock, $0.00001 par value per share | 9.1 | 12,723,026.00 | 06/30/2026 Filed 2026-08-14 | SCHEDULE 13G/AAmendment 1 | Open filing 0001231919-26-000915 Dispute this row |
| Peter Kolchinsky Common Stock, $0.00001 par value per share | 9.1 | 12,723,026.00 | 06/30/2026 Filed 2026-08-14 | SCHEDULE 13G/AAmendment 1 | Open filing 0001231919-26-000915 Dispute this row |
| Rajeev Shah Common Stock, $0.00001 par value per share | 9.1 | 12,723,026.00 | 06/30/2026 Filed 2026-08-14 | SCHEDULE 13G/AAmendment 1 | Open filing 0001231919-26-000915 Dispute this row |
| RA Capital Healthcare Fund, L.P. Common Stock, $0.00001 par value per share | 9.1 | 12,723,026.00 | 06/30/2026 Filed 2026-08-14 | SCHEDULE 13G/AAmendment 1 | Open filing 0001231919-26-000915 Dispute this row |
| BML Investment Partners, L.P. Common Stock, $0.00001 par value | 9.9 | 13,950,000 | 04/23/2026 Filed 2026-04-27 | SCHEDULE 13G/AAmendment 5 | Open filing 0001373604-26-000033 Dispute this row |
| Vivo Opportunity Fund Holdings, L.P. Common Stock, $0.00001 par value | 4.3 | 5,966,370.00 | 03/31/2026 Filed 2026-05-12 | SCHEDULE 13G/AAmendment 1 | Open filing 0001213900-26-055376 Dispute this row |
| Vivo Opportunity, LLC Common Stock, $0.00001 par value | 4.3 | 5,966,370.00 | 03/31/2026 Filed 2026-05-12 | SCHEDULE 13G/AAmendment 1 | Open filing 0001213900-26-055376 Dispute this row |
| Vivo Opportunity Cayman Fund, L.P. Common Stock, $0.00001 par value | 0.5 | 700,296.00 | 03/31/2026 Filed 2026-05-12 | SCHEDULE 13G/AAmendment 1 | Open filing 0001213900-26-055376 Dispute this row |
| Vivo Opportunity Cayman, LLC Common Stock, $0.00001 par value | 0.5 | 700,296.00 | 03/31/2026 Filed 2026-05-12 | SCHEDULE 13G/AAmendment 1 | Open filing 0001213900-26-055376 Dispute this row |
| RA Capital Management, L.P. Common Stock, $0.00001 par value per share | 6.3 | 7,626,705.00 | 03/31/2026 Filed 2026-04-07 | SCHEDULE 13G | Open filing 0001346824-26-000099 Dispute this row |
| Peter Kolchinsky Common Stock, $0.00001 par value per share | 6.3 | 7,626,705.00 | 03/31/2026 Filed 2026-04-07 | SCHEDULE 13G | Open filing 0001346824-26-000099 Dispute this row |
| Rajeev Shah Common Stock, $0.00001 par value per share | 6.3 | 7,626,705.00 | 03/31/2026 Filed 2026-04-07 | SCHEDULE 13G | Open filing 0001346824-26-000099 Dispute this row |
| RA Capital Healthcare Fund, L.P. Common Stock, $0.00001 par value per share | 6.3 | 7,626,705.00 | 03/31/2026 Filed 2026-04-07 | SCHEDULE 13G | Open filing 0001346824-26-000099 Dispute this row |
| The Vanguard Group Common Stock | 0 | 0 | 03/13/2026 Filed 2026-03-26 | SCHEDULE 13G/AAmendment 1 | Open filing 0000102909-26-000505 Dispute this row |
| Deep Track Capital, LP Common Stock, $0.00001 par value | 7.0 | 9,345,000.00 | 03/09/2026 Filed 2026-03-17 | SCHEDULE 13G | Open filing 0001172661-26-001355 Dispute this row |
| Deep Track Biotechnology Master Fund, Ltd. Common Stock, $0.00001 par value | 7.0 | 9,345,000.00 | 03/09/2026 Filed 2026-03-17 | SCHEDULE 13G | Open filing 0001172661-26-001355 Dispute this row |
| David Kroin Common Stock, $0.00001 par value | 7.0 | 9,345,000.00 | 03/09/2026 Filed 2026-03-17 | SCHEDULE 13G | Open filing 0001172661-26-001355 Dispute this row |
| BML Investment Partners, L.P. Common Stock, $0.00001 par value | 11.9 | 14,250,000 | 12/31/2025 Filed 2026-02-09 | SCHEDULE 13G/AAmendment 4 | Open filing 0001373604-26-000008 Dispute this row |
| BlackRock, Inc. Common Stock | 6.2 | 6,700,629 | 12/31/2025 Filed 2026-01-21 | SCHEDULE 13G/AAmendment 1 | Open filing 0002012383-26-000630 Dispute this row |
| Biosion, Inc. Common Stock, $0.00001 par value | 9.4 | 11,281,950 | 12/09/2025 Filed 2026-01-09 | SCHEDULE 13G/AAmendment 1 | Open filing 0000929638-26-000098 Dispute this row |
| Bonita Biotech (HK) Ltd Common Stock, $0.00001 par value | 9.4 | 11,281,950 | 12/09/2025 Filed 2026-01-09 | SCHEDULE 13G/AAmendment 1 | Open filing 0000929638-26-000098 Dispute this row |
| Adage Capital Management, L.P. Common Stock, par value $0.00001 per share | 4.87 | 5,278,144.00 | 09/30/2025 Filed 2025-11-13 | SCHEDULE 13G/AAmendment 2 | Open filing 0000902664-25-004888 Dispute this row |
| Robert Atchinson Common Stock, par value $0.00001 per share | 4.87 | 5,278,144.00 | 09/30/2025 Filed 2025-11-13 | SCHEDULE 13G/AAmendment 2 | Open filing 0000902664-25-004888 Dispute this row |
| Phillip Gross Common Stock, par value $0.00001 per share | 4.87 | 5,278,144.00 | 09/30/2025 Filed 2025-11-13 | SCHEDULE 13G/AAmendment 2 | Open filing 0000902664-25-004888 Dispute this row |
| The Vanguard Group Common Stock | 6.15 | 6,662,063 | 06/30/2025 Filed 2025-07-29 | SCHEDULE 13G | Open filing 0000932471-25-000787 Dispute this row |
| Millennium Management LLC Common Stock, par value $0.00001 per share | 3.5 | 3,837,380.00 | 06/30/2025 Filed 2025-07-24 | SCHEDULE 13G/AAmendment 1 | Open filing 0001104659-25-070388 Dispute this row |
| Millennium Group Management LLC Common Stock, par value $0.00001 per share | 3.5 | 3,837,380.00 | 06/30/2025 Filed 2025-07-24 | SCHEDULE 13G/AAmendment 1 | Open filing 0001104659-25-070388 Dispute this row |
| Israel A. Englander Common Stock, par value $0.00001 per share | 3.5 | 3,837,380.00 | 06/30/2025 Filed 2025-07-24 | SCHEDULE 13G/AAmendment 1 | Open filing 0001104659-25-070388 Dispute this row |
| BlackRock, Inc. Common Stock | 5.1 | 5,471,711 | 06/30/2025 Filed 2025-07-17 | SCHEDULE 13G | Open filing 0002052113-25-002984 Dispute this row |
Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.
What was read
2,550,114 filings read, dated 2004-06-14 to 2026-11-18: Forms 3, 3/A, 4, 4/A, 5, 5/A.
Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.
| Filing year | Filings read |
|---|---|
| 2015 | 17,857 |
| 2016 | 222,642 |
| 2017 | 222,009 |
| 2018 | 223,345 |
| 2019 | 216,482 |
| 2020 | 176,407 |
| 2021 | 249,835 |
| 2022 | 231,682 |
| 2023 | 229,674 |
| 2024 | 234,045 |
| 2025 | 235,520 |
| 2026 | 262,403 |
Filings made before the SEC required XML are listed, not extracted.